Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241132023> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4241132023 abstract "Abstract TAS0728 is an oral covalent binding inhibitor of human epidermal growth factor receptor 2 (HER2). A first-in-human open-label, dose-escalation, phase I study (NCT03410927) was initiated to investigate the safety and dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) and/or recommended phase II dose of TAS0728 in adults with advanced solid tumors with HER2 or HER3 overexpression, amplification or mutation. In total, 19 patients received TAS0728 at escalating doses from 50 to 200 mg BID for 21-day cycles. Following escalation of the dose to 200 mg BID, a total of two DLTs were observed, both cases of Grade 3 diarrhea (lasting >48 hours and not responsive to aggressive antidiarrheal treatment). Following de-escalation of the dose to 150 mg BID, another DLT of Grade 3 diarrhea was observed in one patient. Additionally, at 150 mg BID, one patient had a fatal cardiac arrest after receiving 1 cycle (21 days) of TAS0728. The etiology of the cardiac arrest event was not clear, however causal relationship to TAS0728 could not be excluded due to the temporal association observed. Partial responses were observed in 2 of 14 patients evaluable for TAS0728 treatment response. The study was stopped due to unacceptable toxicity during the dose-escalation as the overall risk-benefit ratio no longer favored the dose level being tested, therefore the MTD was not determined. ClinicalTrials.gov registration number: NCT03410927; registered on January 25, 2018." @default.
- W4241132023 created "2022-05-12" @default.
- W4241132023 creator A5006585898 @default.
- W4241132023 creator A5009562397 @default.
- W4241132023 creator A5018275141 @default.
- W4241132023 creator A5024095268 @default.
- W4241132023 creator A5026538331 @default.
- W4241132023 creator A5041033274 @default.
- W4241132023 creator A5047754769 @default.
- W4241132023 creator A5053506951 @default.
- W4241132023 creator A5059766169 @default.
- W4241132023 creator A5076340516 @default.
- W4241132023 creator A5086593040 @default.
- W4241132023 date "2021-03-15" @default.
- W4241132023 modified "2023-10-16" @default.
- W4241132023 title "A First-in-human Phase I Study of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Patients With Advanced Solid Tumors With HER2 or HER3 Aberrations." @default.
- W4241132023 doi "https://doi.org/10.21203/rs.3.rs-297672/v1" @default.
- W4241132023 hasPublicationYear "2021" @default.
- W4241132023 type Work @default.
- W4241132023 citedByCount "0" @default.
- W4241132023 crossrefType "posted-content" @default.
- W4241132023 hasAuthorship W4241132023A5006585898 @default.
- W4241132023 hasAuthorship W4241132023A5009562397 @default.
- W4241132023 hasAuthorship W4241132023A5018275141 @default.
- W4241132023 hasAuthorship W4241132023A5024095268 @default.
- W4241132023 hasAuthorship W4241132023A5026538331 @default.
- W4241132023 hasAuthorship W4241132023A5041033274 @default.
- W4241132023 hasAuthorship W4241132023A5047754769 @default.
- W4241132023 hasAuthorship W4241132023A5053506951 @default.
- W4241132023 hasAuthorship W4241132023A5059766169 @default.
- W4241132023 hasAuthorship W4241132023A5076340516 @default.
- W4241132023 hasAuthorship W4241132023A5086593040 @default.
- W4241132023 hasBestOaLocation W42411320231 @default.
- W4241132023 hasConcept C126322002 @default.
- W4241132023 hasConcept C178790620 @default.
- W4241132023 hasConcept C180577832 @default.
- W4241132023 hasConcept C185592680 @default.
- W4241132023 hasConcept C197934379 @default.
- W4241132023 hasConcept C2777334693 @default.
- W4241132023 hasConcept C2779802037 @default.
- W4241132023 hasConcept C29730261 @default.
- W4241132023 hasConcept C3018522384 @default.
- W4241132023 hasConcept C71924100 @default.
- W4241132023 hasConcept C90924648 @default.
- W4241132023 hasConcept C98274493 @default.
- W4241132023 hasConceptScore W4241132023C126322002 @default.
- W4241132023 hasConceptScore W4241132023C178790620 @default.
- W4241132023 hasConceptScore W4241132023C180577832 @default.
- W4241132023 hasConceptScore W4241132023C185592680 @default.
- W4241132023 hasConceptScore W4241132023C197934379 @default.
- W4241132023 hasConceptScore W4241132023C2777334693 @default.
- W4241132023 hasConceptScore W4241132023C2779802037 @default.
- W4241132023 hasConceptScore W4241132023C29730261 @default.
- W4241132023 hasConceptScore W4241132023C3018522384 @default.
- W4241132023 hasConceptScore W4241132023C71924100 @default.
- W4241132023 hasConceptScore W4241132023C90924648 @default.
- W4241132023 hasConceptScore W4241132023C98274493 @default.
- W4241132023 hasLocation W42411320231 @default.
- W4241132023 hasOpenAccess W4241132023 @default.
- W4241132023 hasPrimaryLocation W42411320231 @default.
- W4241132023 hasRelatedWork W10386318 @default.
- W4241132023 hasRelatedWork W13890769 @default.
- W4241132023 hasRelatedWork W14180436 @default.
- W4241132023 hasRelatedWork W14852354 @default.
- W4241132023 hasRelatedWork W15036479 @default.
- W4241132023 hasRelatedWork W17437393 @default.
- W4241132023 hasRelatedWork W1749702 @default.
- W4241132023 hasRelatedWork W19355547 @default.
- W4241132023 hasRelatedWork W2497185 @default.
- W4241132023 hasRelatedWork W9130807 @default.
- W4241132023 isParatext "false" @default.
- W4241132023 isRetracted "false" @default.
- W4241132023 workType "article" @default.